Clinical Trial Update: Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

View source ↗

Summary

A neoadjuvant trial evaluating tislelizumab for patients with dMMR/MSI-H stage II-III colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Colo-rectal Cancer (dMMR/MSI-H CRC) | Status: RECRUITING